Twelve Korean companies are part of the TMC Innovation Factory's new residency program. Photo courtesy TMC

The powerful partnership between Texas Medical Center (TMC) innovation and the world of Korean biotech advancement is already growing in scope. Just six months after the new TMC Republic of Korea BioBridge was first announced, 12 new companies from the Republic of Korea will establish on-site presences in Houston to further collaboration between the two nations and medical industries.

The expansion comes from a new agreement between TMC and the Korea Health Industry Development Institute (KHIDI). William McKeon, president and CEO of Texas Medical Center, applauded the move and predicted it would benefit both Houston and Korea immensely.

“Korea has established itself as a global leader in biohealth innovation, with a growing pipeline of breakthrough technologies across digital health, biotechnology, and medical devices,” McKeon said in the news release. “Through the TMC Korea BioBridge, we are creating a direct connection between Korea’s innovators and the world’s largest medical city. This collaboration between TMC and KHIDI provides companies with a place to establish a presence, build strategic relationships, engage with leading clinicians and researchers, and accelerate the path toward commercialization and patient impact in the United States.”

The companies that will be in residence at the TMC Innovation Factory include Ardens Lifescience, whose new CAROL device is currently in human trials tackling lung cancer by using the airway network as electrodes to perform bronchoscopic ablation; stem cell-based gene therapy firm CELLeBRAIN, currently working on neurological disorders and solid cancers; and Wellysis, the developer of the S-Patch wearable cardiac monitoring device.

Additional companies include:

  • Antigravity
  • ARPI
  • CTCELLS
  • elecell
  • HUVER Inc.
  • Hutom
  • ORGANOIDSCIENCES
  • YOUTH BIO GLOBAL
  • Seoul Medical Informatics Intelligence Lab Inc.

“This collaboration establishes a strong foundation for connecting Korea’s biohealth innovation ecosystem with world-class clinical and innovation resources in the United States,” Younghun Jeong, executive director of the KHIDI, added in the news release. “Through partnerships with Texas Medical Center and the Korean-American Medical Association Texas, we look forward to fostering meaningful collaboration among innovators, clinicians, and industry leaders while creating new opportunities for clinical validation, commercialization, and global growth. KHIDI remains committed to expanding global partnerships that support biohealth innovation, clinical collaboration, commercialization, and international growth.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

Eleven medtech startups, hailing from Houston to the Netherlands, have been selected to join TMCi's HealthTech Accelerator. Photo via tmc.edu

TMCi names 11 global startups to latest HealthTech Accelerator cohort

new class

Texas Medical Center Innovation has named 11 medtech startups from around the world to its latest HealthTech Accelerator cohort.

Members of the accelerator's 19th cohort will participate in the six-month program, which kicked off this month. They range from startups developing on-the-go pelvic floor monitoring to 3D-printed craniofacial and orthopedic implants. Each previously participated in TMCi's bootcamp before being selected to join the accelerator. Through the HealthTech Accelerator, founders will work closely with TMC specialists, researchers, top-tier hospital experts and seasoned advisors to help grow their companies and hone their clinical trials, intellectual property, fundraising and more.

“This cohort of startups is tackling some of today’s most pressing clinical challenges, from surgery and respiratory care to diagnostics and women’s health," Tom Luby, chief innovation officer at Texas Medical Center, said in a news release. "At TMC, we bring together the minds behind innovation—entrepreneurs, technology leaders, and strategic partners—to help emerging companies validate, scale, and deliver solutions that make a real difference for patients here and around the world. We look forward to seeing their progress and global impact through the HealthTech Accelerator and the support of our broader ecosystem.”

The 2025 HealthTech Accelerator cohort includes:

  • Houston-based Respiree, which has created an all-in-one cardiopulmonary platform with wearable sensors for respiratory monitoring that uses AI to track breathing patterns and detect early signs of distress
  • College Station-based SageSpectra, which designs an innovative patch system for real-time, remote monitoring of temperature and StO2 for assessing vascular occlusion, infection, and other surgical flap complications
  • Austin-based Dynamic Light, which has developed a non-invasive imaging technology that enables surgeons to visualize blood flow in real-time without the need for traditional dyes
  • Bangkok, Thailand-based OsseoLabs, which develops AI-assisted, 3D-printed patient-specific implants for craniofacial and orthopedic surgeries
  • Sydney, Australia-based Roam Technologies, which has developed a portable oxygen therapy system (JUNO) that provides real-time oxygen delivery optimization for patients with chronic conditions
  • OptiLung, which develops 3D-printed extracorporeal blood oxygenation devices designed to optimize blood flow and reduce complications
  • Bengaluru, India-based Dozee, which has created a smart remote patient monitor platform that uses under-the-mattress bed sensors to capture vital signs through continuous monitoring
  • Montclair, New Jersey-based Endomedix, which has developed a biosurgical fast-acting absorbable hemostat designed to eliminate the risk of paralysis and reoperation due to device swelling
  • Williston, Vermont-based Xander Medical, which has designed a biomechanical innovation that addresses the complications and cost burdens associated with the current methods of removing stripped and broken surgical screws
  • Salt Lake City, Utah-based Freyya, which has developed an on-the-go pelvic floor monitoring and feedback device for people with pelvic floor dysfunction
  • The Netherlands-based Scinvivo, which has developed optical imaging catheters for bladder cancer diagnostics
Here are the eight companies currently being accelerated by Texas Medical Center Innovation. Photo courtesy of TMC

TMC names latest cohort of health tech innovators for 2024 program

ready to grow

The Texas Medical Center Innovation has named its new cohort of health tech companies it's currently accelerating.

This first batch of companies for 2024 was selected from last fall's TMC Bootcamp. Eight of the 10 startups from the bootcamp have moved on to the Accelerator for HealthTech.

"Hailing from diverse corners of the globe—from the tech corridors of Texas and California to Ireland and Australia—these companies converge with a shared mission—to move healthcare forward," Devin Dunn, head of the Accelerator for Health Tech, writes in a TMC blog post. "Through personalized mentorship and guidance, these eight companies are able to navigate complex challenges and refine their strategies, while leveraging the expertise of Texas Medical Center ecosystem to validate their innovations and drive real-world impact."

The selected companies include:

  • AcorAI, from Stockholm, Sweden, which is developing a first-of-its-kind, hand-held, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
  • AirSeal, based in St. Louis, Missouri, which has developed a novel serum-based biomarker technology – circulating fatty acid synthase (cFAS) – that can diagnose cardiovascular and peripheral artery disease with high accuracy in both women and men.
  • Foxo, headquartered in Brisbane, Australia, serves as an interoperable tool designed to enhance clinical collaboration across the healthcare ecosystem. It enables secure, two-way communication with features such as video, voice, screen share, file sharing, and real-time messaging.
  • San Francisco-based Knowtex, an artificial intelligence-powered software writes medical documentation for you and assigns correct codes to ensure proper reimbursement.
  • NeuroBell, from Cork, Ireland, which is working on a novel medical device providing portable EEG monitoring with real-time and automated neonatal seizure alerts at the bedside.
  • Perth, Australia-based OncoRes Medical that's developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure.
  • From right here in Houston, Steradian Technologies, which has created RUMI, the first noninvasive, fully portable infectious disease diagnostic that costs the price of a latte. It uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30 seconds.
  • TYBR, also based in Houston, created a flowable extracellular matrix hydrogel, crafted to safeguard healing tendons and ligaments from scarring and adhesions. The company originated from the TMCi’s Biodesign fellowship and now has entered into the Accelerator for HealthTech to sharpen its regulatory strategy, particularly in anticipation of FDA conversations.

Applications for the next Accelerator for HealthTech will open in May of this year.

BioWell, a Houston accelerator focused on synthetic biology, named its first executive director. Photo via Getty Images

Houston nonprofit synthetic biology accelerator names inaugural executive director

new hire

A Houston accelerator that supports early-stage synthetic biology startups has named its first executive director.

BioWell, which was founded by First Bight Ventures, a Houston-based venture capital group, has announced the appointment of Paul Palmer as executive director. It's the nonprofit organization's first move in assembling its management team. According to his LinkedIn, he's served in the role since November.

“Paul was a clear choice for BioWell because of his combined experience at EY and engagement with Houston’s entrepreneurial community,” First Bight Ventures & BioWell Founder Veronica Wu says in a statement. “Working with large corporations and startups at all levels, he has successfully delivered value-based results for his clients.

"Equally important, Paul has an established relationship with the Houston business community and will be able to leverage his existing network to promote BioWell and our participant entrepreneurs in a public-facing role," she continues.

Palmer was formerly a partner at EY, where he worked on international cross-border tax planning, business development, assurance, and business consulting, as well as working with startups in collaboration with organizations like the Rice Alliance for Technology and Entrepreneurship and Texas Medical Center Innovation.

He joins the BioWell to execute on the organization's mission of "creating an ecosystem that provides hands-on business education, industry mentorship, research, and pilot infrastructure" for the bioeconomy, per the release. He will oversee fundraising, partnerships, sponsorships, and grant opportunities.

He will also lead recruiting for the BioWell's inaugural cohort and securing lab space, which is expected in the coming months.

“Utilizing the resources and expertise of First Bight Ventures, along with our recent EDA grant, BioWell is set to assist with innovation and industrial biology advancements for the United States,” Palmer says in the release.

In December, BioWell, secured $741,925 of the $53 million doled out as a part of the "Build to Scale" Grant program that the U.S. Economic Development Administration, a division of the U.S. Department of Commerce, has established. First Bight was one of 60 organizations to receive funding.

“With the formation of our leadership team, we’re making significant progress on building out the BioWell platform. We are excited about nurturing solutions in industrial biology and helping to establish Houston’s leadership in the global bioeconomy,” he continues.

Mercury Data Science has officially rebranded as OmniScience. Photo via Getty Images

Houston data science firm rebrands to focus on the intersection of AI and life science

introducing OmniScience

A Houston organization established to provide critical data science support to its clients has rebranded and entered into its latest era.

Mercury Data Science has officially rebranded as OmniScience. Founded in 2017 as a spin off of Mercury, a local venture capital group, the data science-focused software company is led by CEO Angela Holmes, who was named to the position in 2022.

"OmniScience signifies our commitment to being a force of innovation in data science and life sciences," Holmes says in the release. "The new brand mirrors our vision for the future, where data science is a driving force for positive change in life sciences."

Angela Holmes is the CEO of OmniScience. Photo via mercuryds.com

Per the news release, the rebranding aligns the company with its mission of supporting innovation at the intersection of biology and data science. The new name reflects the combination of "omniscient" and "science," according to the company.

OmniScience's technology helps its customers across the life science spectrum with navigating key data insights for clinical trials, purpose-built AI development, and other data science services, according to its website.

"This rebrand represents more than just a name change; it signals a bold step into the future, where OmniScience will play a pivotal role in shaping the data science landscape in life sciences," reads the release.

The firm is based out of Texas Medical Center Innovation and has over 20 employees listed on the website.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

TMC names 2024 cohort of cancer treatment innovators

ready to grow

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Abbott assembles expert team to help lure U.S. Space Academy to Texas

space race

State Rep. Greg Bonnen of Friendswood has been tapped to lead a new team that will promote Texas as the future home of the U.S. Space Academy.

Bonnen, a neurosurgeon, chairs Houston Physicians’ Hospital and the powerful Texas House Appropriations Committee. His House district is close to NASA’s Johnson Space Center.

Gov. Greg Abbott appointed the seven-member team. Last month, President Trump signed an executive order establishing the Presidential Commission on the U.S. Space Academy. Commission members, who held their first meeting this month, will recommend a permanent location for the academy.

Texas officials are pushing a site near Johnson Space Center to host the academy. Alabama, Colorado and Florida are among Texas’ competitors.

In a joint statement, U.S. Sen. Ted Cruz and U.S. Rep. Brian Babin, both of Texas, issued a statement backing the state’s bid for the academy. Cruz lives in Houston. Babbin lives in Woodville, about 55 miles south of Beaumont.

“America’s space program is built across the country, but Texas is where the pieces come together,” the lawmakers said. “We are ready to lead the next generation of space pioneers and look forward to showing why Texas is the right home for the U.S. Space Academy.”

The academy’s curriculum will include technical education, leadership development and public service components. Graduates will be set up for careers in the U.S. military, civil service, and aerospace sectors.

The Abbott-appointed team will work with the Texas Space Commission to prepare the state’s proposal for the academy.

In addition to Bonnen, team members with ties to Houston include:

  • Robert Ambrose, who grew up in Houston. He worked at Johnson Space Center before becoming associate director of the Texas A&M Space Institute.
  • Former NASA astronaut Nancy Curry-Gregg, director of the Texas A&M Space Institute. She earned a doctoral degree from the University of Houston and previously worked at Johnson Space Center.
  • Former NASA astronaut Jack Fischer, senior vice president of Houston-based Intuitive Machines. The company builds spacecraft, delivers payloads to the moon and launches satellites.

“Texas is the home of America’s human spaceflight program,” Abbott said in a release. “No state can match what Texas brings to this mission.”

“NASA’s Johnson Space Center, world-class universities, a premier commercial space industry, major military installations, and an unmatched aerospace workforce give Texas every asset the United States Space Academy requires,” the governor added.

Houston space companies take off with new tech, deals and contracts

space update

Space City has had a busy month.

Houston-based aerospace institutions Venus Aerospace, Axiom Space, and Aegis Aerospace have each recently announced advancements in their respective fields that include expansions and new contracts from U.S. and international government agencies.

Here’s the latest:

Venus launches new test stand

Earlier this month, Venus Aerospace added infrastructure to support the ongoing progress of its Rotating Detonation Rocket Engine (RDRE) with the opening of its new propulsion test stand at the Houston Spaceport.

The Texas Space Commission's Space Exploration and Aeronautics Research Fund is funding the test stand, which is part of a larger effort from the state to increase investments in the aerospace economy. The ribbon-cutting event on Sept. 10 welcomed officials from Venus Aerospace, the Texas Space Commission, the Houston Spaceport, Houston business and local community leaders.

With the new stand, Venus will be able to test at higher thrust and for longer durations, which will allow the company to better replicate real-life conditions.

"Building and testing propulsion systems at this pace requires the right infrastructure around the technology," Sassie Duggleby, CEO and co-founder of Venus Aerospace, said in a news release. "We're grateful to the Texas Space Commission and the State of Texas for investing alongside companies like Venus. Public investment like this helps companies move faster and keeps critical aerospace capability growing here in Texas."

Venus closed a $91 million Series B in July and expanded its leadership team.

Axiom partners in Europe

Axiom Space has signed a memorandum of understanding with the European Space Agency for “sustained European access to low-Earth orbit (LEO)” following the retirement of the International Space Station, according to a news release from the company.

Under the agreement, Axiom and the ESA agreed to explore future astronaut missions on the ISS and Axiom Station, research, transportation and spacesuit partnerships. The organizations will explore using the ESA’s European Cargo Return service and potentially a future European crew vehicle to support operations at Axiom Station, the company's forthcoming commercial space station. The partnership could also involve Axiom's AxEMU spacesuit for orbital and lunar applications, according to the release.

“With the upcoming de-orbitation of the ISS, it is our duty to anticipate and prepare future solutions to ensure our access to low-Earth orbit,” Daniel Neuenschwander, director of human and robotic exploration at ESA, said in the release. “The two documents signed today underline both our commitment to safeguard our ability to pursue in-orbit science and to keep offering flight opportunities to our European astronaut corps, as well as the growing interest of international partners for our ongoing project to develop an autonomous European cargo vehicle.”

The announcement comes as Axiom has made several international moves this year. The company shared plans to establish Axiom Space Switzerland this summer and launched Axiom Space Japan in July.

"The path to a sustainable human presence in space runs through international collaboration — reliable supply chains, shared innovation, and partners who bring real capability," Jonathan Cirtain, CEO and President of Axiom Space, said in the release. "Europe's contributions to microgravity science and deep space technology make ESA exactly that kind of partner. This MoU strengthens our work together, and we look forward to ESA and its member states joining us as customers for future astronaut missions."

Aegis expands DoW deal

Webster, Texas-based Aegis Aerospace announced that it has won a new task order to continue supporting the U.S. Space Force’s Space Test Program.

The contract starts in October and covers designing, building, testing and operating Department of War payloads or equipment on NASA, government, and commercial launch vehicles and platforms. The contract was issued by the USSF Space Systems Command, Space Test Program under NASA Johnson Space Center’s Research, Engineering, and Mission Integration Services 2 (REMIS 2).

Currently, the company is working on three payload facilities on the ISS and has plans for two more in development.

“Aegis Aerospace is grateful to continue our exceptional payload integration support to the USSF and the STP to meet their critical mission objectives,” President Matt Ondler added in the release. “This work is more important than ever to maintain U.S. superiority in space. This new contract will take us beyond the current life of the ISS and see us integrate and test payloads on commercial space stations, free-flyers, and cislunar missions.”